OPKO Health: Strong Pipeline Of Drugs, But Not Rushing To Buy

Summary

• OPKO Health has improved its financial position by selling most of BioReference, reducing cash burn, and strengthening its balance sheet.
• Ngenla's profit share with Pfizer has underperformed expectations, but it remains OPKO's main revenue driver as the company pivots to drug development.
• The drug pipeline offers potential, with partnerships and government funding helping to offset development costs, but execution and approvals remain key risks.
• I maintain a Hold rating: OPKO's recent strategic moves are positive, but profitability and pipeline success are still uncertain, so I’m comfortable holding.

Tom Werner/DigitalVision via Getty Images

OPKO Health, Inc. (NASDAQ:OPK) has been a large holding of mine for years. There is a love/hate relationship with the stock (definitely more heavily leaning towards the hate). It has not been a good stock in

Analyst’s Disclosure:I/we have a beneficial long position in the shares of OPK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.